MedTrace Logo

Efficacy and Safety of Generic Imatinib (Carcemia®) Compared to Glivec® in Real-Life Management of Chronic Phase of Chronic Myeloid Leukemia

NCT05282108 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 240

Last updated 2025-03-26

No results posted yet for this study

Summary

The purpose of this study is to evaluate Efficacy and Safety of Generic Imatinib (Carcemia®) Compared to Glivec® in Real-Life Management of Chronic Phase of Chronic Myeloid Leukemia

Conditions

  • Chronic Myeloid Leukemia

Interventions

DRUG

Carcemia

Generic Imatinib

DRUG

Glivec

Imatinib

Sponsors & Collaborators

  • Hikma Pharmaceuticals LLC

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-20
Primary Completion
2026-08-31
Completion
2026-11-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05282108 on ClinicalTrials.gov